SEC Form 4 · accession 0001437749-19-001006
BIOLIFE SOLUTIONS INC · BLFS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd Berard
Officer — Vice President, Marketing
Period of report
Jan 15, 2019
Accepted (ET)
Jan 17, 2019 · 8:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000834365
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 15, 2019 | M | 3,000 | $2.06 | A | 37,583 | D | |
| Common StockF2 | Jan 15, 2019 | S | 3,000 | $12.12 | D | 34,583 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $2.06 | Jan 15, 2019 | M | 3,000 | D | May 4, 2016 | May 4, 2025 | Common Stock | 3,000 | 94,000 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.09 to $12.15, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3Exercisable to the extent of 1/4th thereof on 5/4/16, and remaining balance exercisable to the extent of 1/36th thereof on the 4th day of each month commencing on 6/4/16.